All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @freedomintheslowlane on TikTok · 131s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @freedomintheslowlane's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Day marks officially one week on my drone.
  2. 0:04So how I've been feeling, I've been feeling pretty good.
  3. 0:07I haven't really had a lot of side effects
  4. 0:09that I can tell, right?
  5. 0:10So again, I, oh, I have had one side effect.
  6. 0:14So I did have a little bit of a nauseousness
  7. 0:17right after I took the shot last week
  8. 0:19and I think I told y'all that in one of my previous videos.
  9. 0:22And then, couple of days I was just tired, but again,
  10. 0:26I go to bed really late and then I get up early.
  11. 0:29So that could definitely be a side effect of that.
  12. 0:32The one thing that is constant,
  13. 0:34that the girls was talking about,
  14. 0:35that I should have paid a little bit more attention to
  15. 0:38and took a little bit more seriously was this constipation.
  16. 0:41Okay, because it is real love.
  17. 0:44Okay, it is real.
  18. 0:45I'm drinking tea.
  19. 0:46I'm taking pills.
  20. 0:47I'm doing all the things to try to get stuff moving
  21. 0:50in my stomach.
  22. 0:51Okay, but I don't feel way down.
  23. 0:53Like I just know like,
  24. 0:55hey, I haven't used the bathroom today, right?
  25. 0:58So outside of that though,
  26. 0:59really haven't had a lot of side effects.
  27. 1:02I have definitely changed the way I've been eating
  28. 1:06and definitely been in a cali deficit.
  29. 1:08So haven't been eating anything crazy and it's in sugary,
  30. 1:12haven't drank any alcohol, all that good stuff.
  31. 1:14So definitely doing pretty good on that front.
  32. 1:17Now, the update.
  33. 1:19So my week one progress update for being on 2.5 milligram
  34. 1:24of my jaw is I am down 13.6 pounds.
  35. 1:33Yes, yes, I know, I know.
  36. 1:36I can definitely tell it in the way that I feel.
  37. 1:40I just feel a lot lighter despite being a little constipated.
  38. 1:45I wake up in the morning with a lot more energy.
  39. 1:48Again, I know losing 13.6 pounds in a week
  40. 1:51is not necessarily ideal, but as you all can see,
  41. 1:55I have a lot of way to lose.
  42. 1:58So I know that it will slow down at some point,
  43. 2:01but I think that it's awesome.
  44. 2:04It's a kickstart that has definitely just like
  45. 2:07put me in the mindset and it's like, okay, let's do this.
  46. 2:10Let's do it.
  47. 2:11Let's do it.
  48. 2:12Let's do it.
  49. 2:13Let's do it.

@freedomintheslowlane's week 1 Mounjaro update, fact-checked

FreedomInTheSlowLane

TikTok creator

17.7K viewsWatch on TikTok

Quick answer

The creator is in her first week of tirzepatide at the 2.5mg starting dose, reporting a 13.6-pound scale drop alongside early-onset constipation and nausea consistent with known GLP-1 receptor agonist side effects. Her concurrent dietary changes, including alcohol cessation and carbohydrate reduction, likely contributed substantially to the rapid scale movement through water and glycogen loss rather than fat loss alone. Side effects she described align with SURMOUNT-1 trial data, where nausea and constipation were among the most common adverse events in early titration weeks.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @freedomintheslowlane's week 1 Mounjaro update, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@freedomintheslowlane's week 1 Mounjaro update, fact-checked" from FreedomInTheSlowLane. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is in her first week of tirzepatide at the 2.

The reason this review is not generic is the source wording and the canonical claim label "glp1 week 1 update mounjaro glp1 weightloss progress upda." In this clip, the useful excerpt is: "Day marks officially one week on my drone." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Rapid week-one scale drops on GLP-1 medications typically include substantial water and glycogen loss, which a 2021 NEJM semaglutide review by Wilding et al.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is in her first week of tirzepatide at the 2.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is in her first week of tirzepatide at the 2.5mg starting dose, reporting a 13.6-pound scale drop alongside early-onset constipation and nausea consistent with known GLP-1 receptor agonist side effects. Her concurrent dietary changes, including alcohol cessation and carbohydrate reduction, likely contributed substantially to the rapid scale movement through water and glycogen loss rather than fat loss alone. Side effects she described align with SURMOUNT-1 trial data, where nausea and constipation were among the most common adverse events in early titration weeks.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produces average 20.9% body weight loss over 72 weeks at the highest dose, not in a single week.
  • Rapid week-one scale drops on GLP-1 medications typically include substantial water and glycogen loss, which a 2021 NEJM semaglutide review by Wilding et al. confirmed is a well-documented early-phase pattern.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produces average 20.9% body weight loss over 72 weeks at the highest dose, not in a single week.
  • Rapid week-one scale drops on GLP-1 medications typically include substantial water and glycogen loss, which a 2021 NEJM semaglutide review by Wilding et al. confirmed is a well-documented early-phase pattern.
  • Constipation affected roughly 17% of SURMOUNT-1 participants at 5mg tirzepatide, making it one of the most common early side effects rather than an unusual reaction.
  • Stopping alcohol and cutting sugar simultaneously can drive significant scale movement independent of medication effects, particularly in the first 1-2 weeks.
  • Tirzepatide slows gastric motility as part of its mechanism, meaning hydration is not optional when constipation develops, it is a clinical priority.
  • Week-one results on any GLP-1 medication are not predictive of long-term outcomes and should not be used to benchmark expected progress.
  • Hall and Kahan (2018, Medical Clinics of North America) confirmed in a pharmacotherapy review that early rapid loss in obesity treatment reliably slows as physiological adaptation occurs.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @freedomintheslowlane actually say?

One week into tirzepatide (Mounjaro) at the starting dose of 2.5mg, the creator reported losing 13.6 pounds. She acknowledged this is "not necessarily ideal" but framed it as a motivating kickstart. She also noted nausea right after her first injection, fatigue she partially attributed to poor sleep, and persistent constipation she said she "should have paid a little bit more attention to." She described dietary changes including a caloric deficit, cutting sugar, and stopping alcohol entirely.

To her credit, she flagged the constipation explicitly, avoided dramatizing the weight number, and didn't claim tirzepatide alone caused the loss. That self-awareness matters when we're talking about a video with 17,000+ views on a platform full of people who may be starting the same medication.

Does the science back this up?

Rapid early weight loss on GLP-1 medications is documented, but 13.6 pounds in seven days almost certainly includes significant water weight and glycogen depletion, not just fat. Research supports this reading.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced average weight loss of 20.9% of body weight over 72 weeks at the highest dose, but that's across a year and a half, not a week. Week-one data in clinical trials typically shows 1-3 pounds of loss, though people with more weight to lose, those cutting alcohol, and those in a significant caloric deficit can see larger early drops. A 2021 review by Wilding et al. in NEJM on semaglutide noted that early rapid loss is largely water and stored glycogen, particularly when carbohydrate intake drops sharply. Her cutting alcohol and sugar simultaneously would accelerate this effect considerably.

The side effects she described, including nausea and constipation, are among the most commonly reported in tirzepatide trials. In SURMOUNT-1, constipation affected roughly 17% of participants at the 5mg dose, with onset often in the first weeks.

What did she get wrong (or right)?

She got the side effect profile right. Nausea, fatigue, and constipation are textbook week-one tirzepatide experiences, and she reported them honestly without minimizing or catastrophizing. That's more than a lot of these videos do.

Where the framing gets shaky is the 13.6-pound figure. It's real on the scale, but presenting it as "week one progress" without explaining that a large portion is likely water weight could set unrealistic expectations for other viewers. Someone watching who loses 3 pounds in week one might conclude the medication isn't working for them, when in reality they may be losing more actual fat.

She also didn't mention hydration, which is relevant: GLP-1 medications can reduce thirst alongside appetite, and constipation combined with reduced fluid intake is a real risk in early weeks. That's a gap worth noting, not a catastrophic error, but an important one.

She correctly avoided attributing all the loss to the medication and acknowledged her own dietary changes. That intellectual honesty is worth crediting.

What should you actually know?

If you're starting tirzepatide or any GLP-1 medication and see dramatic week-one scale movement, don't build your expectations around it. A review by Hall and Kahan (2018, Medical Clinics of North America) on obesity pharmacotherapy confirmed that early rapid loss is largely fluid-related, and the rate reliably slows as the body adjusts. The long-term data is strong for tirzepatide specifically, but it works over months, not days.

On constipation: this is a genuinely underreported issue in GLP-1 content. Tirzepatide slows gastric motility as part of how it works. Increasing fiber, staying well hydrated, and talking to a clinician before reaching for laxatives is the appropriate approach. Tea and unspecified "pills" is not a protocol anyone prescribed.

  • Nausea and constipation in week one are expected and well-documented in clinical trials.
  • Large early weight loss on GLP-1 medications typically reflects water and glycogen loss, not fat alone.
  • Stopping alcohol and cutting sugar simultaneously can produce rapid scale drops independent of the medication.
  • Constipation risk is real; hydration is part of managing it, not optional.
  • Week-one results are not predictive of long-term progress on tirzepatide.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

FreedomInTheSlowLane · TikTok creator

17.7K views on this video

Week 1 update! #mounjaro #glp1 #weightloss #progress #update

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed tirzepatide produces average?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produces average 20.9% body weight loss over 72 weeks at the highest dose, not in a single week.

What does the video say about rapid week-one scale drops on glp-1 medications typically include substantial?

Rapid week-one scale drops on GLP-1 medications typically include substantial water and glycogen loss, which a 2021 NEJM semaglutide review by Wilding et al. confirmed is a well-documented early-phase pattern.

What does the video say about constipation affected roughly 17% of surmount-1 participants at 5mg tirzepatide,?

Constipation affected roughly 17% of SURMOUNT-1 participants at 5mg tirzepatide, making it one of the most common early side effects rather than an unusual reaction.

What does the video say about stopping alcohol?

Stopping alcohol and cutting sugar simultaneously can drive significant scale movement independent of medication effects, particularly in the first 1-2 weeks.

What does the video say about tirzepatide slows gastric motility as part of its mechanism, meaning?

Tirzepatide slows gastric motility as part of its mechanism, meaning hydration is not optional when constipation develops, it is a clinical priority.

What does the video say about week-one results on any glp-1 medication?

Week-one results on any GLP-1 medication are not predictive of long-term outcomes and should not be used to benchmark expected progress.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by FreedomInTheSlowLane, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.